Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.65 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.47 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388027 | 0.83 | MAPK14 (0.64) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5391214 | 0.83 | MAPK14 (0.76) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5388345 | 0.82 | MAPK14 (0.57) | MAPK14MAPK10CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5386739 | 0.81 | MAPK14 (0.60) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5388978 | 0.79 | MAPK14 (1.00) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5762620 | 0.74 | MAPK14 (0.52) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5385940 | 0.73 | MAPK14 (0.61) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5890480 | 0.73 | MAPK14 (0.58) | MAPK14CSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5385586 | 0.73 | MAPK14 (0.48) | MAPK14CSNK1D | |
| Gw568326X SCHEMBL5391204 | 0.73 | MAPK14 (0.64) | MAPK14CSNK1A1CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | MAPK14 77/4885MAPK10 140/4885CSNK1A1 198/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885MAPK10 2996/4885CSNK1A1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.